Evidence map›Paper›PMID 39404977›Full record

ArticleBiochemical genetics2025

Establishment of the Prognostic Signature with Genes Related to G2/M Checkpoint in Hepatocellular Carcinoma.

Dapeng Wu, Baiyang Zhu, Zonglong Nie, Qingnuan Kong, Wenjing Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dapeng WuDepartment of Oncology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, 266071, China.ORCID http://orcid.org/0000-0001-9446-8365
Baiyang ZhuSchool of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong Province, China.
Zonglong NieDisease Control Department, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, 266000, China.
Qingnuan KongDepartment of Pathology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, 266071, China. nuanyun4621@126.com.
Wenjing ZhuMedical Research Department, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, 266071, China. zhuwj@uor.edu.cn.ORCID http://orcid.org/0000-0003-0958-0905

Funding

2022 Project on Traditional Chinese Medicine Science and Technology of the Qingdao Municipal Health Commission 2022-zyym14Open Found Project of NMPA Key Laboratory for Quality Research and Evaluation of Traditional Marine Chinese Medicine HYZY-KF-2022009Qingdao Shinan District Science and Technology Plan Project 2022-4-007-YYQingdao Shinan District Science and Technology Plan Project 2022-4-008-YY
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality in the world. Prognostic indicators such as clinicopathological characteristics and single molecular signature are far from satisfactory in clinical practice. More and more researches have suggested that polygenic prognostic features could predict the prognosis of cancer more precisely than single genes nowadays. In this study, we performed gene set enrichment analysis (GSEA) to identify the sets of TCGA hallmark genes. Univariate Cox regression analysis was used to select preliminary genes, and then multivariate Cox regression analysis was used to identify genes associated with overall survival (OS). We also used Kaplan-Meier analysis and receiver operating characteristic (ROC) analysis to validate the prognostic gene signature. Lastly, qRT-PCR was used to evaluate the expression of these genes in clinical samples, and immunohistochemical staining was performed to confirm the signature. A 12-gene signature was finally built and the risk score was significantly associated with the survival of the patients. Subsequent validation by qRT-PCR and immunohistochemical staining in clinical specimens confirmed the value of the risk score in predicting the prognosis. We developed a 12-gene signature that could predict the prognosis of HCC patients. This signature is of high precision and would help identifying subgroups of HCC patients with high or low risk of unfavorable survival.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularGene Expression Regulation, NeoplasticLiver NeoplasmsFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisTranscriptomeBiomarkers, TumorG2/M checkpointGene signatureHepatocellular carcinomaPrognosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.